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TO THE EDITOR
I read with great interest the article by
Krejsgaard et al. (2011) entitled ‘‘Malig-
nant Cutaneous T-Cell Lymphoma Cells
Express IL-17 Utilizing the Jak3/Stat3
Signaling Pathway.’’ The authors con-
clude that the expression of IL-17 by
malignant T cells in cutaneous T-cell
lymphoma (CTCL) lesions is promoted
by the Jak3/Stat3 pathway. I find this
conclusion to be misleading.
The authors studied the role of IL-17
in the pathophysiology of CTCL. Build-
ing on a previous study that showed
IL-17 mRNA in 5 out of 10 biopsies
from CTCL patients (Ciree et al., 2004),
the authors report that biopsies from 10
out of 13 of their CTCL patients
expressed IL-17. To delineate the mo-
lecular basis of IL-17 expression in
CTCL, the authors explored the role of
cytokines that signal through receptors
with the g chain (gc) subunit (IL-2, IL-4,
IL-7, IL-9, IL-15, and IL-21) because
these cytokines have been implicated in
the pathogenesis of CTCL. For example,
gc-cytokines promote the ex vivo survi-
val and proliferation of malignant
T cells (Krejsgaard et al., 2011). A unique
feature of gc-cytokines is that these are
the only cytokines to use Jak3 signaling
(Rochman et al., 2009). Importantly,
malignant T cells from a subset of CTCL
patients were found to contain mutations
in Jak3 that made them constitutively
active (Cornejo et al., 2009); this finding
implicates gc-cytokines because other
than a constitutively active Jak3, the only
other way to activate the Jak3 signaling
pathway is through gc-cytokine binding.
To assess the role of gc-cytokines in IL-17
expression, the authors used two malig-
nant T-cell lines (SeAx and SeZ4) derived
from CTCL patients. The authors report
that both IL-2 and IL-15 increased IL-17
expression. Further, IL-2/IL-15-mediated
expression of IL-17 was blocked by
inhibiting Jak3 both pharmacologically
using Jak3 inhibitors as well as geneti-
cally by Jak3-directed siRNA. Although
these data show the involvement of Jak3
in IL-2- and IL-15-mediated expression of
IL-17, they do not establish a pivotal role
of Jak3 activation in IL-17 expression
because other Jak3 activating gc-cyto-
kines did not affect the IL-17 expression
(as shown in Figure S2 provided by the
authors).
Having said this, I would like to point
out that the authors did not adequately
examine the role of other gc-cytokines in
IL-17 expression. Although the authors
show that these cytokines do not in-
crease IL-17 expression (Figure S2), they
do not provide data on Jak3 activation.
As each cytokine was tested only at a
single concentration, it is possible that
Jak3 was not activated at the concentra-
tion for each cytokine used in the
experiment shown in Figure S2. The
authors should have prepared a dose
response curve for each individual
cytokine to ensure that the concentra-
tion that they used were effective
in activating Jak3. This is important
because although the concentrations
of various cytokines selected by the
authors may be sufficient to activate
their cognate receptors in normal
cells, these concentrations may not be
sufficient to activate their corresponding
receptors once a T cell has undergone
malignant transformation. Thus, in the
absence of data showing the activa-
tion of Jak3 by these cytokines, it
cannot be concluded that other Jak3-
activating cytokines do not modulate
IL-17 expression.
I also want to point out that
CP-690,500, which was used in this
study and is widely accepted in the
literature as a Jak3 selective inhibitor, is
no longer considered to be selective for
Jak3. Recent data, in both enzyme-
based and cell-based assays, indicate
that CP-690,550 inhibits Jak1, Jak2, and
Jak3 with similar affinities (IC50¼3.2 nM
for JAK1, IC50¼4.2 nM for JAK2, and
IC50¼1.6 nM for JAK3; Meyer et al.,
2010). Similarly, WHI-P154, the other
Jak3 inhibitor used in this study, inhibits
Jak2 at comparable concentrations (at
30 mM, WHI-P154 showed a 23þ 4%
inhibition of Jak3 and 16±3.2% of
Jak2; Carbonnelle et al., 2009).
An important question raised by this
study pertains to the variation of expres-
sion of IL-17 in CTCL patients. It is clear
that IL-17 is not expressed in all CTCL
patients. The question arises whether IL-
17 expression denotes a subtype of CTCL
and whether levels of IL-17 correlate with
disease severity. This information would
be useful in designing pharmacological
treatments based on molecular pheno-
types of the tumor.
In summary, the main conclusion
that can be drawn from the data
presented by Krejsgaard et al. (2011) is
that IL-2/IL-15 mediate IL-17 expression
through Jak3 signaling. Whether Jak3
activation alone is sufficient to promote
IL-17 expression remains to be deter-
mined.
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TO THE EDITOR
We are pleased at the interest that
Kwatra (2011) has shown in our article
‘‘Malignant cutaneous T-cell lympho-
ma cells express IL-17 utilizing the
Jak3/Stat3 signaling pathway’’ (Krejs-
gaard et al., 2011) and welcome the
opportunity to discuss the conclusions
drawn from the study.
Kwatra (2011) argues that because
only the two IL-2 receptor b chain
(IL-2Rb) cytokines, IL-2 and IL-15,
but not the other Jak3-activating cyto-
kines utilizing the common cytokine
receptor g chain (gc) increase the
expression of IL-17, it is misleading to
conclude that the Jak3/signal transducer
and activator of transcription 3 (Stat3)
pathway promotes the malignant ex-
pression of IL-17 in cutaneous T-cell
lymphoma (CTCL). Instead, he suggests
that the conclusion that can be drawn
from the study is that IL-2 and IL-15
mediate IL-17 expression through Jak3
signaling. Of notice, this is in agree-
ment with our statement in this article,
namely that ‘‘Our results show that the
IL-2Rb cytokine-induced expression of
IL-17 is mediated through a Jak3/Stat3-
dependent mechanism’’. Thus, the
question is, can Jak3 also promote the
expression of IL-17 in the absence of
IL-2Rb cytokines?
First of all, the malignant T cells
spontaneously produced low amounts
of IL-17 after cytokine starvation, in-
dicating that IL-17 is not exclusively
regulated by IL-2 and IL-15. Second,
although the activity of Jak3 is greatly
increased after stimulation with IL-2Rb
cytokines, it exhibits constitutive activ-
ity in the malignant CTCL cells even
after cytokine starvation (Krejsgaard et al.,
2006). This is possibly through a cyto-
kine-independent mechanism involving
loss of regulatory control by the protein
tyrosine phosphatases and/or suppres-
sors of cytokine signaling (Zhang et al.,
2000; Brender et al., 2005). Third, Jak3
knockdown by small interfering RNA
inhibited the spontaneous IL-17 produc-
tion. Therefore, we do not think that it is
misleading to conclude that our results
indicate Jak3 promotes the expression of
IL-17 by the malignant T cells.
As Kwatra (2011) points out, we are
aware that WHI-P154 inhibits Jak2 and
Jak3 at comparable concentrations and
that recent data have indicated that CP-
690,550 inhibits Jak1 and Jak2 with
similar affinities as Jak3 (Carbonnelle
et al., 2009; Meyer et al., 2010).
However, because we substantiated
the results obtained using the Jak3
inhibitors by the Jak3-directed small
interfering RNA, we think that it justifi-
able to conclude that Jak3 is involved in
promoting the expression of IL-17. That
said, these data do not exclude that the
expression of IL-17 can also be modu-
lated with other members of the Jak
family.
In the study, we primarily focused on
the role of IL-2Rb cytokines in the
malignant secretion of IL-17 and concur
that further studies are needed to fully
establish if other members of the gc
family can modulate the expression of
IL-17 by the malignant T cells. Never-
theless, our data show that relatively
high concentrations of IL-4, IL-7, IL-9,
and IL-21 do not significantly increase
their secretion of IL-17 in vitro. Of
notice, we have confirmed that IL-21
activates the Jak3/Stat3 pathway in
the malignant T cells with minimal
influence on the expression of IL-17
(data not shown). In addition, we found
that some patients were IL-17 negative
even though the malignant T cells exhi-
bited constitutive activation of Stat3.
Accordingly, as discussed in the article,
the capacity of the Jak3/Stat3 pathway
to promote IL-17 expression seems to
be regulated by additional factors. It is
possible that some cytokines, like IL-21,
not only activate the Jak3/Stat3 path-
way but also activate other pathways
that modulate the Jak3-dependent IL-17
expression. Moreover, it seems likely
that the expression of IL-17 is also
modulated by other signaling pathways
and transcription factors that are often
known to be aberrantly regulated in
CTCL (Sors et al., 2006; Krejsgaard
et al., 2009; Kopp et al., 2010). In our
opinion, the present data suggest that
Jak3 promotes the expression of IL-17
by the malignant CTCL cells both in the
presence and in the absence of IL-2 and
IL-15. Therefore, we conclude in the
article that Jak3 promotes the expres-
sion of IL-17, but we also clearly
highlight that this is regulated by other
factors.
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